Hypera S.A (HYPE3) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hypera S.A (HYPE3) has a cash flow conversion efficiency ratio of 0.028x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (R$403.70 Million ≈ $79.21 Million USD) by net assets (R$14.43 Billion ≈ $2.83 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see HYPE3 market cap overview for the company's overall valuation and market capitalisation.
Hypera S.A - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Hypera S.A's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Hypera S.A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hypera S.A ranked by their cash flow conversion efficiency. Explore Hypera S.A cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AUO CORP. SP.ADR NEW/10
F:AU7
|
0.018x |
|
PotlatchDeltic Corp
NASDAQ:PCH
|
0.034x |
|
JUMBO SA UNSP.ADR/1 O.N.
F:5JB1
|
N/A |
|
INVENTURUS KNOWLEDGE SO L
NSE:IKS
|
0.042x |
|
Bilfinger SE
XETRA:GBF
|
0.082x |
|
RXO Inc.
NYSE:RXO
|
-7.323x |
|
Veracyte Inc
NASDAQ:VCYT
|
0.033x |
|
Nelnet Inc
NYSE:NNI
|
0.038x |
Annual Cash Flow Conversion Efficiency for Hypera S.A (2006–2025)
The table below shows the annual cash flow conversion efficiency of Hypera S.A from 2006 to 2025. View HYPE3 live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | R$12.52 Billion ≈ $2.46 Billion |
R$1.43 Billion ≈ $280.27 Million |
0.114x | -45.65% |
| 2024-12-31 | R$12.10 Billion ≈ $2.37 Billion |
R$2.54 Billion ≈ $498.32 Million |
0.210x | +0.88% |
| 2023-12-31 | R$11.52 Billion ≈ $2.26 Billion |
R$2.40 Billion ≈ $470.14 Million |
0.208x | +8.72% |
| 2022-12-31 | R$10.66 Billion ≈ $2.09 Billion |
R$2.04 Billion ≈ $400.05 Million |
0.191x | +34.48% |
| 2021-12-31 | R$9.83 Billion ≈ $1.93 Billion |
R$1.40 Billion ≈ $274.53 Million |
0.142x | +11.14% |
| 2020-12-31 | R$9.24 Billion ≈ $1.81 Billion |
R$1.18 Billion ≈ $232.14 Million |
0.128x | +35.35% |
| 2019-12-31 | R$8.71 Billion ≈ $1.71 Billion |
R$823.88 Million ≈ $161.66 Million |
0.095x | -26.67% |
| 2018-12-31 | R$8.27 Billion ≈ $1.62 Billion |
R$1.07 Billion ≈ $209.27 Million |
0.129x | +7.03% |
| 2017-12-31 | R$7.74 Billion ≈ $1.52 Billion |
R$932.61 Million ≈ $183.00 Million |
0.121x | +19.04% |
| 2016-12-31 | R$8.71 Billion ≈ $1.71 Billion |
R$881.76 Million ≈ $173.02 Million |
0.101x | +151.20% |
| 2015-12-31 | R$8.03 Billion ≈ $1.58 Billion |
R$323.69 Million ≈ $63.51 Million |
0.040x | -54.62% |
| 2014-12-31 | R$7.48 Billion ≈ $1.47 Billion |
R$664.00 Million ≈ $130.29 Million |
0.089x | -5.57% |
| 2013-12-31 | R$7.08 Billion ≈ $1.39 Billion |
R$665.78 Million ≈ $130.64 Million |
0.094x | -9.50% |
| 2012-12-31 | R$6.87 Billion ≈ $1.35 Billion |
R$713.80 Million ≈ $140.06 Million |
0.104x | +19.04% |
| 2011-12-31 | R$6.65 Billion ≈ $1.30 Billion |
R$580.23 Million ≈ $113.85 Million |
0.087x | +556.93% |
| 2010-12-31 | R$5.06 Billion ≈ $992.69 Million |
R$67.24 Million ≈ $13.19 Million |
0.013x | -76.53% |
| 2009-12-31 | R$3.42 Billion ≈ $670.62 Million |
R$193.50 Million ≈ $37.97 Million |
0.057x | +25.23% |
| 2008-12-31 | R$1.92 Billion ≈ $376.06 Million |
R$86.64 Million ≈ $17.00 Million |
0.045x | -78.25% |
| 2007-12-31 | R$692.69 Million ≈ $135.92 Million |
R$143.97 Million ≈ $28.25 Million |
0.208x | +148.26% |
| 2006-12-31 | R$37.40 Million ≈ $7.34 Million |
R$-16.11 Million ≈ $-3.16 Million |
-0.431x | -- |
About Hypera S.A
Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Co… Read more